About APExBIO
Founded in 2009, APExBIO develops research reagents and molecular biology tools for life science and drug discovery applications. Its expertise spans bioactive small molecules, screening libraries, RNA technologies, recombinant proteins and antibodies. The company supports research into oncology, immunology, neuroscience, epigenetics, cell signalling and translational medicine. APExBIO also provides tools for studying biological mechanisms, RNA delivery, gene expression and cellular responses. Its products are supported by analytical validation data, including certificates of analysis, HPLC, MS and NMR documentation.
APExBIO offers an extensive portfolio of small-molecule inhibitors and activators, compound libraries, peptides, assay kits, enzymes and fluorescent labelling reagents. Its RNA Research Solutions portfolio includes EZ Cap™ mRNA products, modified nucleotides, reporter mRNAs and in vitro transcription reagents for mRNA synthesis workflows. The company also supplies recombinant proteins, antibodies and specialised reagents for cell and molecular biology research. These technologies support drug discovery, target validation, high-throughput screening, RNA delivery studies, gene expression analysis and therapeutic development.
Europa Biosite’s subsidiaries distribute for APExBIO in Denmark, Estonia, Finland, Iceland, Ireland, Norway, Sweden, Switzerland and the United Kingdom.